398 related articles for article (PubMed ID: 24775734)
1. Prion-like aggregation of mutant p53 in cancer.
Silva JL; De Moura Gallo CV; Costa DC; Rangel LP
Trends Biochem Sci; 2014 Jun; 39(6):260-7. PubMed ID: 24775734
[TBL] [Abstract][Full Text] [Related]
2. Mutant p53 aggregates into prion-like amyloid oligomers and fibrils: implications for cancer.
Ano Bom AP; Rangel LP; Costa DC; de Oliveira GA; Sanches D; Braga CA; Gava LM; Ramos CH; Cepeda AO; Stumbo AC; De Moura Gallo CV; Cordeiro Y; Silva JL
J Biol Chem; 2012 Aug; 287(33):28152-62. PubMed ID: 22715097
[TBL] [Abstract][Full Text] [Related]
3. Expanding the prion concept to cancer biology: dominant-negative effect of aggregates of mutant p53 tumour suppressor.
Silva JL; Rangel LP; Costa DC; Cordeiro Y; De Moura Gallo CV
Biosci Rep; 2013 Jul; 33(4):. PubMed ID: 24003888
[TBL] [Abstract][Full Text] [Related]
4. Aggregation and Prion-Like Properties of Misfolded Tumor Suppressors: Is Cancer a Prion Disease?
Costa DC; de Oliveira GA; Cino EA; Soares IN; Rangel LP; Silva JL
Cold Spring Harb Perspect Biol; 2016 Oct; 8(10):. PubMed ID: 27549118
[TBL] [Abstract][Full Text] [Related]
5. Modulation of p53 and prion protein aggregation by RNA.
Cordeiro Y; Vieira T; Kovachev PS; Sanyal S; Silva JL
Biochim Biophys Acta Proteins Proteom; 2019 Oct; 1867(10):933-940. PubMed ID: 30826454
[TBL] [Abstract][Full Text] [Related]
6. Targeting the Prion-like Aggregation of Mutant p53 to Combat Cancer.
Silva JL; Cino EA; Soares IN; Ferreira VF; A P de Oliveira G
Acc Chem Res; 2018 Jan; 51(1):181-190. PubMed ID: 29260852
[TBL] [Abstract][Full Text] [Related]
7. The aggregation of mutant p53 produces prion-like properties in cancer.
Rangel LP; Costa DC; Vieira TC; Silva JL
Prion; 2014; 8(1):75-84. PubMed ID: 24509441
[TBL] [Abstract][Full Text] [Related]
8. Sulfated glycosaminoglycans mediate prion-like behavior of p53 aggregates.
Iwahashi N; Ikezaki M; Nishikawa T; Namba N; Ohgita T; Saito H; Ihara Y; Shimanouchi T; Ino K; Uchimura K; Nishitsuji K
Proc Natl Acad Sci U S A; 2020 Dec; 117(52):33225-33234. PubMed ID: 33318190
[TBL] [Abstract][Full Text] [Related]
9. p53 reactivation with induction of massive apoptosis-1 (PRIMA-1) inhibits amyloid aggregation of mutant p53 in cancer cells.
Rangel LP; Ferretti GDS; Costa CL; Andrade SMMV; Carvalho RS; Costa DCF; Silva JL
J Biol Chem; 2019 Mar; 294(10):3670-3682. PubMed ID: 30602570
[TBL] [Abstract][Full Text] [Related]
10. Pressure-temperature folding landscape in proteins involved in neurodegenerative diseases and cancer.
Cordeiro Y; Foguel D; Silva JL
Biophys Chem; 2013 Dec; 183():9-18. PubMed ID: 23849959
[TBL] [Abstract][Full Text] [Related]
11. Structural basis of restoring sequence-specific DNA binding and transactivation to mutant p53 by suppressor mutations.
Suad O; Rozenberg H; Brosh R; Diskin-Posner Y; Kessler N; Shimon LJ; Frolow F; Liran A; Rotter V; Shakked Z
J Mol Biol; 2009 Jan; 385(1):249-65. PubMed ID: 18996393
[TBL] [Abstract][Full Text] [Related]
12. p53 amyloid formation leading to its loss of function: implications in cancer pathogenesis.
Ghosh S; Salot S; Sengupta S; Navalkar A; Ghosh D; Jacob R; Das S; Kumar R; Jha NN; Sahay S; Mehra S; Mohite GM; Ghosh SK; Kombrabail M; Krishnamoorthy G; Chaudhari P; Maji SK
Cell Death Differ; 2017 Oct; 24(10):1784-1798. PubMed ID: 28644435
[TBL] [Abstract][Full Text] [Related]
13. Role of p53 isoforms and aggregations in cancer.
Kim S; An SS
Medicine (Baltimore); 2016 Jun; 95(26):e3993. PubMed ID: 27368003
[TBL] [Abstract][Full Text] [Related]
14. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
Stiewe T; Haran TE
Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
[TBL] [Abstract][Full Text] [Related]
15. The Status of p53 Oligomeric and Aggregation States in Cancer.
de Oliveira GAP; Petronilho EC; Pedrote MM; Marques MA; Vieira TCRG; Cino EA; Silva JL
Biomolecules; 2020 Apr; 10(4):. PubMed ID: 32260447
[TBL] [Abstract][Full Text] [Related]
16. Amyloidogenicity of p53: a hidden link between protein misfolding and cancer.
Gong H; Yang X; Zhao Y; Petersen RB; Liu X; Liu Y; Huang K
Curr Protein Pept Sci; 2015; 16(2):135-46. PubMed ID: 25692950
[TBL] [Abstract][Full Text] [Related]
17. Co-localization of mutant p53 and amyloid-like protein aggregates in breast tumors.
Levy CB; Stumbo AC; Ano Bom AP; Portari EA; Cordeiro Y; Silva JL; De Moura-Gallo CV
Int J Biochem Cell Biol; 2011 Jan; 43(1):60-4. PubMed ID: 21056685
[TBL] [Abstract][Full Text] [Related]
18. Prion-like p53 Amyloids in Cancer.
Navalkar A; Ghosh S; Pandey S; Paul A; Datta D; Maji SK
Biochemistry; 2020 Jan; 59(2):146-155. PubMed ID: 31603660
[TBL] [Abstract][Full Text] [Related]
19. Self-aggregation and coaggregation of the p53 core fragment with its aggregation gatekeeper variant.
Lei J; Qi R; Wei G; Nussinov R; Ma B
Phys Chem Chem Phys; 2016 Mar; 18(11):8098-107. PubMed ID: 26923710
[TBL] [Abstract][Full Text] [Related]
20. Dual role of p53 amyloid formation in cancer; loss of function and gain of toxicity.
Lasagna-Reeves CA; Clos AL; Castillo-Carranza D; Sengupta U; Guerrero-Muñoz M; Kelly B; Wagner R; Kayed R
Biochem Biophys Res Commun; 2013 Jan; 430(3):963-8. PubMed ID: 23261448
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
